Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo) when taken immediately or within 4 hours of onset3,4
Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY 50 mg) vs 13% (placebo).3 Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)1
UBRELVY has been prescribed over 2 million times by more than 80,000 HCPs, treating over 500,000 patients3
POWERFUL: Zero pain, sustained1,3
Pain freedom at 2 hours (co-primary endpoint) was demonstrated in 21% (UBRELVY® 50 mg) vs 13% (placebo).1,3 Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo)1,3,4
RAPID: Quick pain relief1
Pain relief at 2 hours was demonstrated in 62% (UBRELVY 50 mg) vs 49% (placebo) when taken immediately or within 4 hours of onset1,3,5
PRE-HEADACHE: Clinical evidence3
Absence of headache pain of moderate to severe intensity within 24 hours after dosing in the pre-headache phase (primary endpoint)3
INDICATION
UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.
Get patients started
Once you've decided to prescribe UBRELVY, enable access for your patients with our U-CONCIERGE program and learn how eligible patients may pay as little as $0—all pills, all fills.†
Help enable access
16-count pack is available for your UBRELVY patients
Migraine attacks can be unpredictable.6 Prepare your patients with a 16-count package of UBRELVY 100 mg tablets.
View dosing
Many patients experience
pre-headache symptoms7
See the results of administering UBRELVY during the pre-headache phase of a migraine attack.
Explore pre-headache data*In clinical studies, patients took UBRELVY within 4 hours of a migraine attack.5
†Patient out-of-pocket costs may vary. Terms and Conditions apply. This offer is only valid for commercially insured patients. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs.
CONTRAINDICATIONS
Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).
Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.
ADVERSE REACTIONS
The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).
DRUG INTERACTIONS
DOSAGE AND ADMINISTRATION
UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.
US-UBR-230117
References: 1. UBRELVY. Package insert. AbbVie Inc; 2023. 2. Retail weekly prescription data from IQVIA as of 01/23. 3. Data on file. AbbVie Inc. 4. Goadsby PJ, Blumenfeld AM, Lipton RB, et al. Time course of efficacy of ubrogepant for the acute treatment of migraine: clinical implications. Cephalalgia. 2021;41(5):546-560. 5. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898. 6. Serrano D, Lipton RB, Scher Al, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101. 7. Lipton RB, Reed ML, Fanning KM, Contreras-De Lama J, Adams AM, Buse DC. Characterizing the pre- and post-headache phases of migraine: interim results from the CaMEO-International Study (US sample). Poster presented at: 64th Annual Scientific Meeting of the American Headache Society; June 9-12, 2022; Denver, CO.
